IP Library Granted Patent US 7,321,038
Granted Patent B2
US 7,321,038 · App. 10/973,031 · Granted Jan 22, 2008

Method for the catalytic production of hydrocodone and hydromorphone

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,321,038
App. No.
10/973,031
Granted
Jan 22, 2008
Kind
B2
Abstract

A method for the catalytic conversion of codeine, morphine or analogs thereof into hydrocodone, hydromorphone or analogs thereof utilizing a transition metal catalyst of the formula [M(PR 3 R 4 R 5 ) n X m ] p ; wherein R 1 is H, alkyl, aryl or acyl; M is a Group VIII transition metal; R 3 , R 4 and R 5 are selected from the group consisting of alkyl, aryl, alkoxyl, phenoxyl and combinations thereof; X is a halide or an anion; n is 1, 2, 3 or 4; m is 1 or 2; and p is at least 1.

Claims (35)

1. A method comprising catalytically converting a compound of Formula I into a compound of Formula II utilizing at least one transition metal complex of the formula [M(PR 3 R 4 R 5 ) n X m ] p ; wherein R 1 is H, alkyl, aryl or acyl; M is a Group VIII transition metal; R 3 , R 4 and R 5 are selected from the group consisting of alkyl, aryl, alkoxyl, phenoxyl and combinations thereof; X is H, a halide or an anion; n is 1, 2, 3 or 4; m is 1 or 2; and p is at least 1.

2. The method of claim 1 wherein R 1 is H or CH3.

3. The method of claim 1 wherein (PR 3 R 4 R 5 ) n is supported by a solid.

4. The method of claim 1 wherein (PR 3 R 4 R 5 ) n is selected from the group consisting of polymer supported (PR 3 R 4 R 5 ) n , silical supported (PR 3 R 4 R 5 ) n , resin-bound (PR 3 R 4 R 5 ) n and mixtures thereof.

5. The method of claim 1 wherein the metal complex is bound to a tertiary copolymer selected from the group consisting of styrene, divinylbenzene, and diphenyl(p-vinylphenyl)phosphine.

6. The method of claim 5 wherein the copolymer is substituted with a monomer selected from the group consisting of ethylene dimethacrylate, p-bromostyrene, divinylbenzene, butadiene, diallyl maleate, diallyl phthalate, glycol dimethacrylate, diolefins and triolefins.

7. The method of claim 1 wherein the metal complex is of the formula [Rh(PR 3 R 4 R 5 ) n X m ] p ; R 3 , R 4 and R 5 are selected from the group consisting of alkyl, aryl, alkoxyl, phenoxyl , and combinations thereof; X is a halide or an anion; n is 1, 2, 3 or 4; m is 1 or 2; and p is at least 1.

8. The method of claim 7 wherein n is 1, 2 or 3; p is at least 1; and X is selected from the group consisting of BF 4 , PF 6 , CIO 4 , CHO 2 , CF 3 CO 2 , CF 3 SO 3 , CH 3 CO 2 , ArCO 2 , CH 3 SO 3 , p-tolylSO 3 , HSO4 and H 2 PO 4 .

9. The method of claim 1 wherein in the metal complex is of the formula [RuXY(PR 3 R 4 R 5 ) n ] p ; R 3 , R 4 and R 5 are selected from the group consisting of alkyl, aryl, alkoxyl, phenoxyl and combinations thereof; X is an H, halide or an anion; Y is an H, halide or an anion; n is 1, 2, 3 or 4; m is 1 or 2; and p is at least 1.

10. The method of claim 9 wherein n=3, p is at least 1, Y=H and X=Cl; or n=3, p is at least 1, Y=H and X=H; or n=4, p is at least 1, X=H, Y=H; or n=2, 3 or 4 and X=Y is selected from the group consisting of CIO 4 , PF 6 , BF 4 , CHO 2 , CF 3 CO 2 , CF 3 SO 3 , CH 3 CO 2 , ArCO 2 , CH 3 SO 3 , p-tolylSO 3 , HSO4 and H 2 PO 4 .

11. A method comprising catalytically converting a compound of Formula I into a compound of Formula II utilizing at least one transition metal complex of a tertiary phosphine halide, wherein R 1 is H, alkyl, aryl or acyl; the metal complex is of the formula [M(PR 2 3 ) n X m ] p wherein M is a Group VIII transition metal; R 2 is an alkyl or aryl; X is H, a halide or an anion; n is 1, 2, 3 or 4; p is at least 1; and m is 1 or 2

12. The method of claim 11 wherein R 1 is H or CH 3 .

13. The method of claim 11 wherein the metal complex is of the formula [Rh(PR 2 3 ) n X] p , wherein R 2 is an alkyl or aryl; X is a halide or an anion; n is 1, 2 or 3; and p is at least 1.

14. The method of claim 13 wherein the metal complex is of the formula [Rh(PR 2 3 ) n Y] p , wherein n is 1, 2 or 3; p is at least 1; and Y is selected from the group consisting of BF 4 , PF 6 , CIO 4 , CHO 2 , CF 3 CO 2 , CF 3 SO 3 , CH3CO 2 , ArCO 2 , CH 3 SO 3 , p-tolylSO 3 , HSO4 and H 2 PO 4 .

15. The method of claim 11 wherein in the metal complex is of the formula [RuX 2 (PR 2 3 ) n ] p wherein R 2 is an alkyl or aryl; X is a halide; n is 1, 2, 3 or 4; and p is at least 1.

16. The method of claim 11 wherein the metal complex is of the formula [RuYX(PR 2 3 ) n ] p wherein R 2 is an alkyl or aryl and wherein n=3, p is at least 1, Y=H and X=Cl; or n=3, p is at least 1, Y=H and X=H; or n=4, p is at least 1, X=H, Y=H; or n=2, 3 or 4 and X=Y is selected from the group consisting of CIO 4 , CHO 2 , PF 6 , BF 4 . CHO 2 , CF 3 CO 2 , CF 3 SO 3 , CH 3 CO 2 , ArCO 2 , CH 3 SO 3 , p-tolylSO 3 , HSO 4 and H 2 PO 4 .

17. A method for producing hydrocodone comprising converting codeine into hydrocodone in the presence of at least one transition metal complex of the formula [M(PR 3 R 4 R 5 ) n X m ] p ; wherein M is a Group VIII transition metal; R 3 , R 4 and R 5 are selected from the group consisting of alkyl, aryl, alkoxyl, phenoxyl and combinations thereof; X is H, a halide or an anion; n is 1, 2, 3 or 4; m is 1 or 2; and p is at least 1.

18. The method of claim 17 wherein (PR 3 R 4 R 5 ) n is supported by a solid.

19. The method of claim 17 wherein (PR 3 R 4 R 5 ) n is selected from the group consisting of polymer supported (PR 3 R 4 R 5 ) n , silical supported (PR 3 R 4 R 5 ) n , resin-bound (PR 3 R 4 R 5 ) n and mixtures thereof.

20. The method of claim 17 wherein the metal complex is of the formula [Rh(PR 2 3 ) n X] p , wherein R 2 is an alkyl or aryl; X is a halide or an anion; n is 1, 2 or 3; and p is at least 1.

21. The method of claim 17 wherein the metal complex is of the formula [Rh(PR 2 3 ) n Y] p , wherein R 2 is an alkyl or aryl; n is 1, 2 or 3; p is at least 1; and Y is selected from the group consisting of BF 4 , PF 6 , CIO 4 , CHO 2 , CF 3 CO 2 , CF 3 SO 3 , CH 3 CO 2 , ArCO 2 , CH 3 SO 3 , p-tolylSO 3 , HSO4 and H 2 PO 4 .

22. The method of claim 17 wherein in the metal complex is of the formula [RuX 2 (PR 2 3 ) n ] p wherein R 2 is an alkyl or aryl; X is a halide; n is 1, 2, 3 or 4; and p is at least 1.

23. The method of claim 17 wherein the metal complex is of the formula [RuYX(PR 2 3 ) n ] p wherein R 2 is an alkyl or aryl and wherein n=3, p is at least 1, Y=H and X=Cl; or n=3, p is at least 1, Y=H and X=H; or n4, X=H, Y=H; or n=2, 3 or 4, p is at least 1 and X=Y is selected from the group consisting of CIO 4 , CHO 2 , PF 6 , BF 4 , CHO 2 , CF 3 CO 2 , CF 3 SO 3 CH 3 CO 2 , ArCO 2 , CH 3 SO 3 , p-tolylSO 3 , HSO4 and H 2 PO 4 .

24. A method for producing hydromorphone comprising converting morphine into hydromorphone in the presence of at least one transition metal complex of a tertiary phosphine wherein the metal complex is of the formula [M(PR 2 3 ) n X m ] p wherein M is a Group VIII -transition metal, R 2 is an alkyl or aryl; X is H, a halide or an anion; n is 1, 2, 3 or 4; p is at least 1; and m is 1 or 2.

25. The method of claim 24 wherein the metal complex is of the formula [Rh(PR 2 3 ) n X] p , wherein R 2 is an alkyl or aryl; X is a halide or an anion; n is 1, 2 or 3; and p is at least 1.

26. The method of claim 24 wherein the metal complex is of the formula [Rh(PR 2 3 ) n Y] p , wherein R 2 is an alkyl or aryl; n is 1, 2 or 3; p is at least 1; and Y is selected from the group consisting of BF 4 , PF 6 , CIO 4 CF 3 CO 2 , CF 3 SO 3 , CH 3 CO 2 , ArCO 2 , CH 3 SO 3 , p-tolylSO 3 , HSO4 and H 2 PO 4 .

27. The method of claim 24 wherein in the metal complex is of the formula [RuX 2 (PR 2 3 ) n ] p wherein R 2 is an alkyl or aryl; X is a halide; n is 1, 2, 3 or 4; and p is at least 1.

28. The method of claim 24 wherein the metal complex is of the formula [RuYX(PR 2 3 ) n ] p wherein R 2 is an alkyl or aryl and wherein n=3, Y=H and X=Cl; or n=3, Y=H, p is at least 1 and X=H; or n=4, p is at least 1, X=H, Y=H; or n=2, 3 or 4, p is at least 1 and X=Y is selected from the group consisting of CIO 4 , PF 6 , BF 4 , CF 3 CO 2 , CF 3 SO 3 , CH 3 CO 2 , ArCO 2 , CH 3 SO 3 , p-tolylSO 3 , HSO4 and H 2 PO 4 .

29. An improved metal catalyst recovery method comprising:

a) catalytically converting a compound of Formula I into a compound of Formula II utilizing at least one transition metal complex of a tertiary phosphine of the formula [M(PR 3 R 4 R 5 ) n X m ] p ; wherein R 1 is H, alkyl, aryl or acyl;

M is a Group VIII transition metal; R 3 , R 4 and R 5 are selected from the group consisting of alkyl, aryl, alkoxyl, phenoxyl and combinations thereof; X is a halide or an anion; n is 1, 2, 3 or 4; m is 1 or 2; and p is at least 1; and

b) recovering the metal containing solid catalyst.

30. The method of claim 29 wherein R 1 is H or CH 3 .

31. The method of claim 29 wherein (PR 3 R 4 R 5 ) n is supported by a solid.

32. The method of claim 29 wherein (PR 3 R 4 R 5 ) n is selected from the group consisting of polymer supported (PR 3 R 4 R 5 ) n , silical supported (PR 3 R 4 R 5 ) n , resin-bound (PR 3 R 4 R 5 ) n and mixtures thereof.

Assignments (4)
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 032480, FRAME 0001 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: THERAKOS, INC.; MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065609/0322 →
SECURITY INTEREST Recorded Mar 19, 2014
From: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS INC.; MALLINCKRODT CARIBBEAN, INC.; MALLINCKRODT US POOL LLC; MALLINCKRODT INC.; LUDLOW CORPORATION; CNS THERAPEUTICS, INC.; ENTERPRISES HOLDINGS, INC.; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS, INC; MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC; MALLINCKRODT ENTERPRISES HOLDINGS, INC.
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 032480/0001 →
CHANGE OF LEGAL ENTITY Recorded Aug 16, 2011
From: MALLINCKRODT INC.
To: MALLINCKRODT LLC
Reel/Frame 026754/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 10, 2004
From: WANG, PETER XIANQI; WHITE, CARL RAY
To: MALLINCKRODT INC.
Reel/Frame 015434/0282 →